Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says

Novo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday. Semaglutide, the active ingredient in Ozempic, was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in patients with Type 2 diabetes compared with seven other diabetes medications. That includes insulin and older so-called GLP-1 drugs similar to Ozempic, the resea ...